Antidiabetics Market 2027 By Product, Patient, Route of Administration and Geography | The Insight Partners

Antidiabetics Market to 2027 - Global Analysis and Forecasts by Product (Insulin, Drug Class); Patient (Pediatric, Adult, Geriatric); Route of Administration (Insulin Pump, Insulin Syringe/ Insulin Pen, Intravenous Infusion, Oral, Others) and Geography

Report Code: TIPRE00004579 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Antidiabetic is commonly used to manage diabetes with the help of antidiabetic agent. Antidiabetic agent is a substance that help a person with diabetes control their level of glucose (sugar) in the blood. It include insulin and hypoglycemic agent.

MARKET DYNAMICS
The antidiabetics market is expected to grow during the forecast period due to the changing life style and consumption of unhealthy food is increasing globally diabetes disease. Rising incidence of diabetes will result into substantial rise in demand for antidiabetic. Growing R&D activities is likely to show positive impact on market growth. Raising awareness of treatment is one of the biggest opportunity for antidiabetics market in the emerging nations.

MARKET SCOPE
The "Global Antidiabetics Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of antidiabetics market with detailed market segmentation by product type, drug class, and geography. The global antidiabetics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading antidiabetics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global antidiabetics market is segmented on the basis of product, patient and route of administration. Based on products, the market is segmented as insulin and drug class. On the basis of patient, the global antidiabetics market is classify into pediatric, adult and geriatric. Based on route of administration, the market segmented into insulin pump, insulin syringe or insulin pen, intravenous infusion, oral and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global antidiabetics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The antidiabetics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting antidiabetics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the antidiabetics market in these regions.

MARKET PLAYERS
The reports cover key developments in the antidiabetics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from antidiabetics market are anticipated to lucrative growth opportunities in the future with the rising demand for antidiabetics market in the global market. Below mentioned is the list of few companies engaged in the antidiabetics market.

The report also includes the profiles of key antidiabetics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Johnson & Johnson
  • Bayer Corporation AG
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Novo Nordisk
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antidiabetics Market - By Product
1.3.2 Antidiabetics Market - By Patient
1.3.3 Antidiabetics Market - By Route of Administration
1.3.4 Antidiabetics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTIDIABETICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIDIABETICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTIDIABETICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIDIABETICS - GLOBAL MARKET OVERVIEW
6.2. ANTIDIABETICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIDIABETICS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. INSULIN
7.3.1. Overview
7.3.2. Insulin Market Forecast and Analysis
7.3.3. Rapid Acting Analog Market
7.3.3.1. Overview
7.3.3.2. Rapid Acting Analog Market Forecast and Analysis
7.3.4. Long Acting Analog Market
7.3.4.1. Overview
7.3.4.2. Long Acting Analog Market Forecast and Analysis
7.3.5. Premixed Insulin Market
7.3.5.1. Overview
7.3.5.2. Premixed Insulin Market Forecast and Analysis
7.3.6. Short Acting Analog Market
7.3.6.1. Overview
7.3.6.2. Short Acting Analog Market Forecast and Analysis
7.3.7. Intermediate Acting insulin Market
7.3.7.1. Overview
7.3.7.2. Intermediate Acting insulin Market Forecast and Analysis
7.4. DRUG CLASS
7.4.1. Overview
7.4.2. Drug Class Market Forecast and Analysis
7.4.3. Alpha Glucosidase Inhibitors Market
7.4.3.1. Overview
7.4.3.2. Alpha Glucosidase Inhibitors Market Forecast and Analysis
7.4.4. Biguanides Market
7.4.4.1. Overview
7.4.4.2. Biguanides Market Forecast and Analysis
7.4.5. Sulphonylureas Market
7.4.5.1. Overview
7.4.5.2. Sulphonylureas Market Forecast and Analysis
7.4.6. GLP-1 (Glucagon like Peptide) Agonists Market
7.4.6.1. Overview
7.4.6.2. GLP-1 (Glucagon like Peptide) Agonists Market Forecast and Analysis
7.4.7. DPP-IV (Dipeptidyl Peptidase) Inhibitors Market
7.4.7.1. Overview
7.4.7.2. DPP-IV (Dipeptidyl Peptidase) Inhibitors Market Forecast and Analysis
7.4.8. Meglitinides Market
7.4.8.1. Overview
7.4.8.2. Meglitinides Market Forecast and Analysis
7.4.9. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors Market
7.4.9.1. Overview
7.4.9.2. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors Market Forecast and Analysis
7.4.10. Thiazolidinedione Market
7.4.10.1. Overview
7.4.10.2. Thiazolidinedione Market Forecast and Analysis
8. ANTIDIABETICS MARKET - REVENUE AND FORECASTS TO 2027 - PATIENT
8.1. OVERVIEW
8.2. PATIENT POPULATION MARKET FORECASTS AND ANALYSIS
8.3. PEDIATRIC
8.3.1. Overview
8.3.2. Pediatric Market Forecast and Analysis
8.4. ADULT
8.4.1. Overview
8.4.2. Adult Market Forecast and Analysis
8.5. GERIATRIC
8.5.1. Overview
8.5.2. Geriatric Market Forecast and Analysis
9. ANTIDIABETICS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. INSULIN PUMP
9.3.1. Overview
9.3.2. Insulin Pump Market Forecast and Analysis
9.4. INSULIN SYRINGE/ INSULIN PEN
9.4.1. Overview
9.4.2. Insulin Syringe/ Insulin Pen Market Forecast and Analysis
9.5. INTRAVENOUS INFUSION
9.5.1. Overview
9.5.2. Intravenous Infusion Market Forecast and Analysis
9.6. ORAL
9.6.1. Overview
9.6.2. Oral Market Forecast and Analysis
9.7. OTHERS
9.7.1. Overview
9.7.2. Others Market Forecast and Analysis
10. ANTIDIABETICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Antidiabetics Market Overview
10.1.2 North America Antidiabetics Market Forecasts and Analysis
10.1.3 North America Antidiabetics Market Forecasts and Analysis - By Product
10.1.4 North America Antidiabetics Market Forecasts and Analysis - By Patient Population
10.1.5 North America Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.1.6 North America Antidiabetics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Antidiabetics Market
10.1.6.1.1 United States Antidiabetics Market by Product
10.1.6.1.2 United States Antidiabetics Market by Patient Population
10.1.6.1.3 United States Antidiabetics Market by Route of Administration
10.1.6.2 Canada Antidiabetics Market
10.1.6.2.1 Canada Antidiabetics Market by Product
10.1.6.2.2 Canada Antidiabetics Market by Patient Population
10.1.6.2.3 Canada Antidiabetics Market by Route of Administration
10.1.6.3 Mexico Antidiabetics Market
10.1.6.3.1 Mexico Antidiabetics Market by Product
10.1.6.3.2 Mexico Antidiabetics Market by Patient Population
10.1.6.3.3 Mexico Antidiabetics Market by Route of Administration
10.2. EUROPE
10.2.1 Europe Antidiabetics Market Overview
10.2.2 Europe Antidiabetics Market Forecasts and Analysis
10.2.3 Europe Antidiabetics Market Forecasts and Analysis - By Product
10.2.4 Europe Antidiabetics Market Forecasts and Analysis - By Patient Population
10.2.5 Europe Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.2.6 Europe Antidiabetics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Antidiabetics Market
10.2.6.1.1 Germany Antidiabetics Market by Product
10.2.6.1.2 Germany Antidiabetics Market by Patient Population
10.2.6.1.3 Germany Antidiabetics Market by Route of Administration
10.2.6.2 France Antidiabetics Market
10.2.6.2.1 France Antidiabetics Market by Product
10.2.6.2.2 France Antidiabetics Market by Patient Population
10.2.6.2.3 France Antidiabetics Market by Route of Administration
10.2.6.3 Italy Antidiabetics Market
10.2.6.3.1 Italy Antidiabetics Market by Product
10.2.6.3.2 Italy Antidiabetics Market by Patient Population
10.2.6.3.3 Italy Antidiabetics Market by Route of Administration
10.2.6.4 Spain Antidiabetics Market
10.2.6.4.1 Spain Antidiabetics Market by Product
10.2.6.4.2 Spain Antidiabetics Market by Patient Population
10.2.6.4.3 Spain Antidiabetics Market by Route of Administration
10.2.6.5 United Kingdom Antidiabetics Market
10.2.6.5.1 United Kingdom Antidiabetics Market by Product
10.2.6.5.2 United Kingdom Antidiabetics Market by Patient Population
10.2.6.5.3 United Kingdom Antidiabetics Market by Route of Administration
10.2.6.6 Rest of Europe Antidiabetics Market
10.2.6.6.1 Rest of Europe Antidiabetics Market by Product
10.2.6.6.2 Rest of Europe Antidiabetics Market by Patient Population
10.2.6.6.3 Rest of Europe Antidiabetics Market by Route of Administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Antidiabetics Market Overview
10.3.2 Asia-Pacific Antidiabetics Market Forecasts and Analysis
10.3.3 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Product
10.3.4 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Patient Population
10.3.5 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.3.6 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Antidiabetics Market
10.3.6.1.1 Australia Antidiabetics Market by Product
10.3.6.1.2 Australia Antidiabetics Market by Patient Population
10.3.6.1.3 Australia Antidiabetics Market by Route of Administration
10.3.6.2 China Antidiabetics Market
10.3.6.2.1 China Antidiabetics Market by Product
10.3.6.2.2 China Antidiabetics Market by Patient Population
10.3.6.2.3 China Antidiabetics Market by Route of Administration
10.3.6.3 India Antidiabetics Market
10.3.6.3.1 India Antidiabetics Market by Product
10.3.6.3.2 India Antidiabetics Market by Patient Population
10.3.6.3.3 India Antidiabetics Market by Route of Administration
10.3.6.4 Rest of Asia-Pacific Antidiabetics Market
10.3.6.4.1 Rest of Asia-Pacific Antidiabetics Market by Product
10.3.6.4.2 Rest of Asia-Pacific Antidiabetics Market by Patient Population
10.3.6.4.3 Rest of Asia-Pacific Antidiabetics Market by Route of Administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Antidiabetics Market Overview
10.4.2 Middle East and Africa Antidiabetics Market Forecasts and Analysis
10.4.3 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Product
10.4.4 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Patient Population
10.4.5 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.4.6 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Antidiabetics Market
10.4.6.1.1 South Africa Antidiabetics Market by Product
10.4.6.1.2 South Africa Antidiabetics Market by Patient Population
10.4.6.1.3 South Africa Antidiabetics Market by Route of Administration
10.4.6.2 Saudi Arabia Antidiabetics Market
10.4.6.2.1 Saudi Arabia Antidiabetics Market by Product
10.4.6.2.2 Saudi Arabia Antidiabetics Market by Patient Population
10.4.6.2.3 Saudi Arabia Antidiabetics Market by Route of Administration
10.4.6.3 U.A.E Antidiabetics Market
10.4.6.3.1 U.A.E Antidiabetics Market by Product
10.4.6.3.2 U.A.E Antidiabetics Market by Patient Population
10.4.6.3.3 U.A.E Antidiabetics Market by Route of Administration
10.4.6.4 Rest of Middle East and Africa Antidiabetics Market
10.4.6.4.1 Rest of Middle East and Africa Antidiabetics Market by Product
10.4.6.4.2 Rest of Middle East and Africa Antidiabetics Market by Patient Population
10.4.6.4.3 Rest of Middle East and Africa Antidiabetics Market by Route of Administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Antidiabetics Market Overview
10.5.2 South and Central America Antidiabetics Market Forecasts and Analysis
10.5.3 South and Central America Antidiabetics Market Forecasts and Analysis - By Product
10.5.4 South and Central America Antidiabetics Market Forecasts and Analysis - By Patient Population
10.5.5 South and Central America Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.5.6 South and Central America Antidiabetics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Antidiabetics Market
10.5.6.1.1 Brazil Antidiabetics Market by Product
10.5.6.1.2 Brazil Antidiabetics Market by Patient Population
10.5.6.1.3 Brazil Antidiabetics Market by Route of Administration
10.5.6.2 Argentina Antidiabetics Market
10.5.6.2.1 Argentina Antidiabetics Market by Product
10.5.6.2.2 Argentina Antidiabetics Market by Patient Population
10.5.6.2.3 Argentina Antidiabetics Market by Route of Administration
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTIDIABETICS MARKET, KEY COMPANY PROFILES
12.1. ELI LILLY COMPANY
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BAYER CORPORATION AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. JOHNSON AND JOHNSON
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ASTRAZENECA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVO NORDISK
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK AND CO
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANOFI
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Johnson & Johnson
2. Bayer Corporation AG
3. AstraZeneca
4. Sanofi
5. Novartis AG
6. Bristol-Myers Squibb Company
7. Merck & Co., Inc.
8. Eli Lilly and Company
9. Pfizer Inc.
10. Novo Nordisk